ATE261313T1 - Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten - Google Patents

Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten

Info

Publication number
ATE261313T1
ATE261313T1 AT96932269T AT96932269T ATE261313T1 AT E261313 T1 ATE261313 T1 AT E261313T1 AT 96932269 T AT96932269 T AT 96932269T AT 96932269 T AT96932269 T AT 96932269T AT E261313 T1 ATE261313 T1 AT E261313T1
Authority
AT
Austria
Prior art keywords
ultrafiltration
producing
proteosomeamphiphilic
diafiltration
vaccine
Prior art date
Application number
AT96932269T
Other languages
English (en)
Inventor
George H Lowell
Wendell D Zollinger
James F Wood
Original Assignee
Us Army Medical Res Materiel C
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21707938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE261313(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Army Medical Res Materiel C, Id Biomedical Corp Quebec filed Critical Us Army Medical Res Materiel C
Application granted granted Critical
Publication of ATE261313T1 publication Critical patent/ATE261313T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT96932269T 1995-09-18 1996-09-18 Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten ATE261313T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US385995P 1995-09-18 1995-09-18
PCT/US1996/015002 WO1997010844A1 (en) 1995-09-18 1996-09-18 Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Publications (1)

Publication Number Publication Date
ATE261313T1 true ATE261313T1 (de) 2004-03-15

Family

ID=21707938

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96932269T ATE261313T1 (de) 1995-09-18 1996-09-18 Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten

Country Status (20)

Country Link
US (1) US6476201B1 (de)
EP (1) EP0854729B2 (de)
JP (2) JP4033489B2 (de)
KR (1) KR19990045763A (de)
CN (1) CN1211192A (de)
AT (1) ATE261313T1 (de)
BR (1) BR9610484A (de)
CA (1) CA2232410C (de)
CZ (1) CZ298460B6 (de)
DE (1) DE69631835T3 (de)
DK (1) DK0854729T3 (de)
EA (1) EA199800208A1 (de)
ES (1) ES2217325T5 (de)
HU (1) HUP9901577A3 (de)
IL (1) IL123720A (de)
MX (1) MX9802128A (de)
NO (1) NO320074B1 (de)
PL (1) PL325604A1 (de)
PT (1) PT854729E (de)
WO (1) WO1997010844A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1999061053A1 (en) * 1998-05-29 1999-12-02 Chiron Corporation Combination meningitidis b/c vaccines
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
EP1721618A3 (de) * 2000-02-15 2007-01-10 ID Biomedical Corporation of Quebec Proteasom-influenzavirus-impfstoffzusammensetzung
CA2400468C (en) 2000-02-15 2012-12-18 Intellivax International Inc. Proteosome influenza vaccine
NZ521531A (en) 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
US7524509B2 (en) 2001-03-09 2009-04-28 Id Biomedical Corporation Of Quebec Proteosome-liposaccharide vaccine adjuvant
US20060057160A1 (en) * 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
US20050152919A1 (en) * 2003-09-15 2005-07-14 Id Biomedical Corporation Of Quebec Measles subunit vaccine
WO2005042017A1 (en) 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
CN101039691B (zh) 2004-06-25 2013-07-31 魁北克益得生物医学公司 用于治疗神经疾病的组合物和方法
EP1778283A2 (de) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccinzusammensetzungen zur behandlung von coronavirusinfektion
US7552948B2 (en) 2006-03-29 2009-06-30 Tokai Rubber Industries, Ltd. Quick connector
CN110064053A (zh) * 2006-08-07 2019-07-30 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
BRPI0715396B8 (pt) * 2006-08-07 2021-05-25 Harvard College método de produção de uma composição para vacina
EP2069054A1 (de) * 2006-08-30 2009-06-17 GE Healthcare Bio-Sciences Corp. System und verfahren zur charakterisierung von membranen und membranfiltriervorrichtungen
UA99659C2 (uk) * 2008-05-30 2012-09-10 Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
CN102686238A (zh) * 2009-09-09 2012-09-19 马特里瓦克斯研究和开发公司 具有改善的免疫原性的蛋白质基质疫苗
AU2015321698B2 (en) * 2014-09-24 2018-06-28 The United States Of America As Represented By The Secretary Of The Navy Combined enterotoxigenic Escherichia coli and Campylobacter jejuni recombinant construct
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU1522494C (ru) * 1987-06-16 1994-11-15 Научно-производственное объединение "Иммунопрепарат" Способ получения инактивированной вакцины гриппа
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
EP0449958B9 (de) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcales klasse i-aussenmembranprotein-vakzin
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
CA2139517A1 (en) * 1992-07-20 1994-02-03 Paul M. Keller Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
CA2400468C (en) * 2000-02-15 2012-12-18 Intellivax International Inc. Proteosome influenza vaccine

Also Published As

Publication number Publication date
NO981189L (no) 1998-05-14
WO1997010844A1 (en) 1997-03-27
DE69631835T2 (de) 2005-02-10
BR9610484A (pt) 2001-09-11
HUP9901577A3 (en) 2000-03-28
ES2217325T5 (es) 2009-04-01
DE69631835T3 (de) 2009-03-05
IL123720A (en) 2002-02-10
CN1211192A (zh) 1999-03-17
MX9802128A (es) 1998-11-29
JP2000507913A (ja) 2000-06-27
US6476201B1 (en) 2002-11-05
CA2232410C (en) 2003-06-17
CZ298460B6 (cs) 2007-10-10
EP0854729A1 (de) 1998-07-29
ES2217325T3 (es) 2004-11-01
US20020164357A1 (en) 2002-11-07
EP0854729B2 (de) 2008-10-22
EP0854729A4 (de) 2000-02-02
DE69631835D1 (de) 2004-04-15
PT854729E (pt) 2004-08-31
KR19990045763A (ko) 1999-06-25
EP0854729B1 (de) 2004-03-10
DK0854729T3 (da) 2004-07-12
NO320074B1 (no) 2005-10-17
JP4033489B2 (ja) 2008-01-16
NO981189D0 (no) 1998-03-17
JP2004099619A (ja) 2004-04-02
CA2232410A1 (en) 1997-03-27
IL123720A0 (en) 1998-10-30
PL325604A1 (en) 1998-08-03
EA199800208A1 (ru) 1998-10-29
CZ81998A3 (cs) 1998-10-14
HUP9901577A2 (hu) 1999-08-30

Similar Documents

Publication Publication Date Title
ATE261313T1 (de) Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten
DE69423383D1 (de) Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
EP1297844A3 (de) Meningokokkus Multikomponentimpfstoff
AP1690A (en) Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup A and process for the production thereof.
RU98101249A (ru) Омр26 антиген haemophylus influenzae
FI102616B1 (fi) Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen tyyppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä
SE9003278L (sv) Foerfarande respektive anlaeggning foer beredning av en medicinsk loesning, t ex en dialysloesning
ATE138923T1 (de) Verfahren zur herstellung gereinigter glycolipide durch membrantrennverfahren
SE9003198D0 (sv) Fish vaccine comprising a virulent, invasive bacterium
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
ES2560452T3 (es) Vacuna de IPV-DPT
JP2002537352A (ja) ナイセリアワクチン組成物および方法
CH662056A5 (fr) Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies.
DE3850257D1 (de) Verfahren zur herstellung tierärztlicher acellularer impfstoffe gegen gramnegative momenterische pathogene bazillen.
ATE218369T1 (de) Verfahren zur herstellung von immunoaktiven mittel und impfstoffe
EP0082072B1 (de) Verfahren zur Herstellung eines biochemischen Vakzins gegen Salmonellenfieber
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
ATE199059T1 (de) Herstellung eines tetanusimpfstoffes
DE69804850D1 (de) Verfahren zur herstellung eines kappa-casein-glykomakropeptides oder eines abkoemmlings davon
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
Rappaport et al. Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen
ES2037599B1 (es) Metodo de cultivo para la preparacion de una vacuna tifoidea oral de tipo vivo
IT1206250B (it) Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
DE68913212D1 (de) Ein reines faktor i-protein und verfahren zur herstellung.
WO2003073984A3 (en) Tat as an immunogen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0854729

Country of ref document: EP

REN Ceased due to non-payment of the annual fee